Advances in immunotherapy for the treatment of glioblastoma
Open Access
- 14 October 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Neuro-Oncology
- Vol. 131 (1), 1-9
- https://doi.org/10.1007/s11060-016-2299-2
Abstract
Glioblastoma (GBM) is an aggressive brain tumour, associated with extremely poor prognosis and although there have been therapeutic advances, treatment options remain limited. This review focuses on the use of immunotherapy, harnessing the power of the host’s immune system to reject cancer cells. Key challenges in glioma specific immunotherapy as with many other cancers are the limited immunogenicity of the cancer cells and the immunosuppressive environment of the tumour. Although specific antigens have been identified in several cancers; brain tumours, such as GBM, are considered poorly immunogenic. However, as detailed in this review, strategies aimed at circumventing these challenges are showing promise for GBM treatment; including identification of glioma specific antigens and endogenous immune cell activation in an attempt to overcome the immunosuppressive environment which is associated with GBM tumours. An up-to-date summary of current Phase I/II and ongoing Phase III GBM immunotherapy clinical trials is provided in addition to insights into promising preclinical approaches which are focused predominantly on increased induction of Type 1 helper T cell (Th1) immune responses within patients.Funding Information
- Irish Cancer Society (CRF13TIV)
- Science Foundation Ireland (14/IA/2582, 12/IA/1421, SFI/12/RC/2278)
- Erasmus
This publication has 57 references indexed in Scilit:
- YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cellsJournal of Translational Medicine, 2013
- The microglial activation state regulates migration and roles of matrix-dissolving enzymes for invasionJournal of Neuroinflammation, 2013
- Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastomaCancer Immunology, Immunotherapy, 2012
- Viral Vector-Based Therapeutic Cancer VaccinesThe Cancer Journal, 2011
- Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb studyNeuro-Oncology, 2010
- Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastomaImmunology, 2010
- Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumorsNeuro-Oncology, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncologyNeuro-Oncology, 2008
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004